Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Shenzhen Builds Up R&D Platform For New Combination Drugs

This article was originally published in PharmAsia News

Executive Summary

Shenzhen National Biomedical Industry Base recently released its key R&D results at China Hi-Tech Fair. Last March, Shenzhen Ausa Pharmed Co., which has been appointed the new combination drug research center for the biomedical base, received Class I new drug certification from China's State FDA for its enalapril maleate and folic acid tablet. This represents the only new drug with intellectual property rights to obtain such certification in the cardiovascular field in the past three years. Experts observe that innovative drug combination, complemented with expansion of drug indications, may form an effective approach that suits China's situation and helps the nation catch up in the global innovation competition. (Click here for more - Chinese Language)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts